Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
S.Korea’s Lunit installs breast cancer AI diagnostic tool at 200 US hospitals
Lunit Inc., a South Korean AI-powered cancer diagnostics company, said on Monday that more than 200 healthcare institutions across the US have now a...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Boryung, Lotus Pharma signs CDMO deal on anticancer injection
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...
SK Biopharm submits NDA of epilepsy drug to China
South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...
President of Latvia visits S.Korea's Daan Cancer Lab
Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Hanmi Pharma to move up launch of anti-obesity drug
South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca
Lunit Inc., a South Korean AI-powered cancer diagnostics company, has partnered with global biopharma giant AstraZeneca plc. to jointly enter the AI...
Volpara to supply breast cancer SW to US Defense Health Agency
Lunit, a South Korean cancer diagnostics AI company, said on Monday its US subsidiary Volpara Health secured a 10 billion won ($7.5 million) contr...
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Celltrion to supply breast, stomach cancer treatment to Brazil
Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...
After 37 years of use, Kim returns trusty microwave to Samsung with love
For 37 years, a simple microwave made by Samsung Electronics Co. sat in the kitchen of Kim Kyu-won, providing much more than convenience.It was ther...
SK Group’s 3rd-generation daughter comes to the fore
Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...
Gencurix, Hitachi to cooperate on molecular diagnostics
South Korean biotech company Gencurix Inc. said on Tuesday that it will cooperate with Japan's Hitachi High-Tech Corporation to enter the Japanese c...
Volpara to supply cancer diagnostics SW to Intermountain Health
Lunit, a South Korean cancer diagnostics AI company, announced on Wednesday that its subsidiary Volpara Health, a New Zealand-based AI software deve...
Yuhan’s lung cancer drug clears FDA hurdle for global debut
A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...
